跳至主要内容
临床试验/NCT03052036
NCT03052036进行中(未招募)不适用

The British Heart Foundation Older Patients With Non-ST SEgmeNt elevatIOn myocaRdial Infarction Randomized Interventional TreAtment Trial

Newcastle-upon-Tyne Hospitals NHS Trust74 个研究点 分布在 1 个国家目标入组 1,518 人开始时间: 2016年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1,518
试验地点
74
主要终点
Time to cardiovascular death or non-fatal MI (defined by the fourth universal definition) from randomization

研究概览

简要总结

SENIOR-RITA is a multicentre prospective open-label trial randomizing patients presenting with type 1 NSTEMI aged ≥75 years between invasive and conservative treatment strategies, to compare time from randomisation to cardiovascular death or non-fatal MI

详细描述

The population is getting older and heart artery disease is the biggest killer in the UK. Over recent years, there have been improvements in medications and technologies to treat it, but these have been primarily tested in younger patients. Previous research studies suggest that older patients (75 years and over) are not well represented in clinical research and these patients in particular those that are frail and those with co-morbidities are less likely to receive advanced medications and medical procedures. The current study will enrol patients 75 years and over, presenting with a heart attack. If patients agree to participate, they will be randomly allocated to one of two treatment groups. In the first group, patients will receive the latest medications recommended in heart attack. In the second group, in addition to these medications, patients will have coronary angiography. This will show whether they have any blockages in heart arteries. If appropriate, coronary revascularisation by percutaneous coronary intervention (PCI) commonly known as coronary angioplasty or coronary artery bypass grafting, sometimes called CABG (a surgical procedure in which a blood vessel from the leg, arm or chest is used to bypass a narrowed section of a coronary artery) will be carried out. During the trial, frailty scores, cognition measures, co-morbidity indices, questionnaires on quality of life, NHS and personal social services utilization will be collected from the participant and in addition proxy quality of life information will be collected from the participant's carers. Investigators will evaluate which one of the two treatment groups will do better and live longer. Investigators will also collect information on their quality of life and frailty measures for a 5 year period. The trial hopes to recruit 2300 patients from approximately 30 centres across the UK.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
75 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥ 75 years
  • Type 1 NSTEMI during index hospitalisation

排除标准

  • Patients presenting with STEMI or unstable angina
  • Patients with cardiogenic shock
  • Patients with known life expectancy <1 year
  • Patients in whom neither the patient nor the consultee are able and willing to provide written informed consent
  • Previous inclusion in the BHF SENIOR-RITA trial
  • Inability to undergo invasive coronary angiography, such as no vascular access site, or absolute contraindication to coronary revascularisation

结局指标

主要结局

Time to cardiovascular death or non-fatal MI (defined by the fourth universal definition) from randomization

时间窗: Up to 5 years

To determine the impact of a routine invasive strategy on cardiovascular death and non-fatal myocardial infarction (MI) compared with a conservative treatment strategy in older patients (≥75 years) with NSTEMI.

次要结局

  • Bleeding(Up to 1 year)
  • Recurrent myocardial infarction(Up to 5 years)
  • Hospitalisation for heart failure(Up to 5 years)
  • Urgent coronary revascularisation(Up to 5 years)
  • Recurrent hospitalisation for myocardial infarction(Up to 5 years)
  • Stroke(Up to 5 years)
  • Length of time spent at home(Up to 5 years)
  • All cause, cardiovascular and non-cardiovascular death rates(Up to 5 years)
  • Fried and Rockwood frailty scores(Up to 5 years)
  • Procedural complications(Within 7 days of invasive care)
  • Quality of Life using EQ-5D-5L and quality adjusted life years (QALY)(Up to 5 years)
  • Costs to the NHS and personal social services(Up to 5 years)
  • 25% increase in serum creatinine concentration(Within 7 days of invasive care)
  • Incremental cost per QALY gained at 1 year(Up to 5 years)
  • Renal replacement therapy(Within 7 days of invasive care)

研究者

发起方
Newcastle-upon-Tyne Hospitals NHS Trust
申办方类型
Other
责任方
Sponsor

研究点 (74)

Loading locations...

相似试验

已完成
不适用
A study to evaluate the benefit of medical therapy versus angiography and stenting in patients with heart attacks - The BHF SENIOR RITA Trialon-ST segment elevation myocardial infarctionCirculatory SystemAcute subendocardial myocardial infarction
ISRCTN11343602The Newcastle Upon Tyne Hospitals NHS Foundation Trust1,516
已完成
不适用
Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide.Multiple Myeloma
NL-OMON25186Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center; Erasmus MC; Postbus 2040; 3000 CA Rotterdam Tel: +31 10 704 1560; Fax +31 10 704 1028 e-mail: hdc@erasmusmc.nl668
已完成
2 期
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus CancerAdenocarcinoma of the Esophagogastric JunctionGastric Cancer
NCT00737373Krankenhaus Nordwest143
已完成
不适用
Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone.Multiple myeloma
NL-OMON25578Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl420
招募中
不适用
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)ElderlyAntineoplastic AgentsCardiotoxicity
NCT03711110Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514